Discovery of C-imidazole azaheptapyridine FPT inhibitors.

[1]  Jun Liang,et al.  The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity. , 2008, Bioorganic & medicinal chemistry letters.

[2]  C. Toulas,et al.  Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme. , 2007, International journal of radiation oncology, biology, physics.

[3]  W. R. Bishop,et al.  Enhanced FTase activity achieved via piperazine interaction with catalytic zinc. , 2006, Bioorganic & medicinal chemistry letters.

[4]  G. Daley,et al.  Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy , 2006, Cancer.

[5]  W. R. Bishop,et al.  The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling , 2005, Journal of Biological Chemistry.

[6]  W. R. Bishop,et al.  Farnesyltransferase inhibitors as anticancer agents: critical crossroads. , 2004, Current opinion in drug discovery & development.

[7]  L. Beese,et al.  Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. , 2004, Biochemistry.

[8]  G. Ahmann,et al.  Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. , 2004 .

[9]  I. M. Bell.  Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy? , 2004, Journal of medicinal chemistry.

[10]  P. Muller,et al.  Synthesis Routes Towards the Farnesyl Protein Transferase Inhibitor ZARNESTRATM , 2004 .

[11]  C. Baum,et al.  Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations. , 2003, Current topics in medicinal chemistry.

[12]  S. Chong,et al.  Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. , 2000, Journal of medicinal chemistry.

[13]  W. R. Bishop,et al.  A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. , 2000, Cancer research.

[14]  P. Weber,et al.  Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships. , 1999, Journal of medicinal chemistry.

[15]  W. R. Bishop,et al.  Novel Tricyclic Inhibitors of Farnesyl Protein Transferase , 1995, The Journal of Biological Chemistry.